---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-009808"
form_type: "8-K"
ticker: "BCAX"
cik: "0002023658"
company_name: "Bicara Therapeutics Inc."
filed_at: "2026-02-19T23:59:59+00:00"
generated_at: "2026-05-16T01:50:33.268712+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bicara Phase 1b data: ficerafusp alfa 2000mg Q2W shows 48% ORR, 26% CR in 1L HPV-negative HNSCC

## Summary
- 48% confirmed ORR and 26% complete response rate in 27 patients with 1L HPV-negative R/M HNSCC.
- 77% of responders achieved deep responses (≥80% tumor shrinkage); median time to response 1.6 months.
- Safety profile consistent with known profile of ficerafusp alfa plus pembrolizumab; generally well tolerated.
- Company plans to develop loading and every-three-week maintenance regimen pending regulatory alignment.
- Median PFS, DoR, and OS not yet estimable; data continue to mature.

## SEC filing metadata
- accession: 0001628280-26-009808
- form_type: 8-K
- ticker: BCAX
- cik: 0002023658
- company_name: Bicara Therapeutics Inc.
- filed_at: 2026-02-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023658/000162828026009808/0001628280-26-009808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023658/000162828026009808/bcax-20260219.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-009808
- JSON: https://secwatch.observer/filing/0001628280-26-009808.json
- Plain text: https://secwatch.observer/filing/0001628280-26-009808.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.